February 2026 Options Now Available For Colgate-Palmolive (CL)

Colgate-Palmolive (CL) is trading at $80.07 and Stock Options Channel highlights a $79 put trading with a $0.10 bid (cost basis $78.90 if sold-to-open) and a $81 call trading with a $0.05 bid for a covered-call. The $79 put is ~1% out-of-the-money with a 58% probability of expiring worthless (yield boost 0.13% or 1.05% annualized); the $81 covered call is ~1% OTM with a 54% chance of expiring worthless (yield boost 0.06% or 0.52% annualized) and a potential 1.22% total return if called at the Feb 2026 expiry. Implied volatilities are 24% (put) and 21% (call) versus a 12-month trailing volatility of 21%; the piece serves as an options strategy note for investors considering buy-write or put-selling approaches.

Analysis

Market structure: These option setups primarily benefit income-seeking option sellers and brokers (collecting commissions) while imposing assignment risk on those sellers; the premium math is trivial (put premium = $0.10 → 0.13% cash commitment, 1.05% annualized), so flows will be marginal versus CL’s market cap and unlikely to move the stock materially. The near parity of implied (21–24%) and realized (21%) volatility signals a balanced supply/demand in CL options — limited skew and no systemic volatility dislocation.

Risk assessment: Immediate (days) effects are theta decay and potential assignment around inflection events (earnings, CPI); short-term (weeks/months) risk is a gap-down from a consumer demand shock or FX swing that would leave put-sellers exposed; long-term (quarters/years) tail risks include sustained margin compression, regulatory recall, or brand erosion — a >10% revenue decline would materially change option economics. Hidden dependencies include broker margining/assignment timing and dividend/earnings dates; catalysts to watch: next CL earnings, US CPI, and IV rank moves >5 pts.

Trade implications: Direct plays: conservative defined-risk trades (sell 79/75 put spread) are preferable to naked puts given the tiny premium; covered-call on $81 is a low-opportunity-cost yield boost only if you’re content capping upside at ~1.2% to Feb 2026. Position sizing should be small: target 1–3% portfolio per strategy, close or hedge if IV jumps >5 pts or CL gaps below $77.

Contrarian angles: The consensus “easy yield” trade underestimates execution costs — commissions and margin often erase the 0.13% payoff, so naked put-selling is over-promoted. Historical parallels: low-vol staples frequently gap on macro surprises despite steady fundamentals; a cluster of assigned puts could create short-term buying followed by forced selling if sellers de-risk, amplifying moves contrary to naive expectations.

Key Decisions for Investors

• Sell-to-open CL Feb 2026 $79 put (naked) only as a tactical acquisition tool: limit exposure to 1–2% of portfolio notional (e.g., 1 contract per $100k AUM), target effective entry ≤ $78.90; pre-define exit if CL < $77 or IV rises >5 pts from trade entry.
• Prefer defined-risk alternative: sell CL Feb 2026 79/75 put spread sized to 1–3% portfolio — caps max loss to ~$4 minus credit; close spread if mark-to-market loss >30% of max loss or IV falls >5 pts.
• If owning CL shares, sell Feb 2026 $81 covered calls to generate ≈0.06% extra carry (annualized ~0.5%); position size 1–3% portfolio and accept being called at $81 (1.2% total return to expiry).
• Rotate 1–2% from high-beta discretionary (e.g., XLY) into staples (e.g., XLP or CL) to gain defensive carry; fund this by trimming cyclicals and set reversion trigger to reallocate if CL outperforms by >5% or IV compresses >3 pts.